Search Results - "Rosenberg, Ari Joseph"

Neoantigen evolution in head and neck cancer progression: where do we go from here? by Rosenberg, Ari Joseph, Izumchenko, Evgeny

Get full text

Multimodality Therapy for Locoregional Nasopharyngeal Carcinoma-A Decision Tool for Treatment Optimization by Rosenberg, Ari Joseph

Get full text

Xevinapant with radiation and concurrent carboplatin and paclitaxel in patients ineligible for cisplatin with locoregionally advanced squamous cell carcinoma of the head and neck (EXtRaCT study) by Mir, Nabiel Ali, Juloori, Aditya, Swiecicki, Paul, Katipally, Rohan Reddy, Agrawal, Nishant, Blair, Elizabeth A., Haraf, Daniel J., Pearson, Alexander T., Vokes, Everett E., Rosenberg, Ari Joseph

“…TPS6126 Background: Locoregionally advanced (LA) head and neck cancer (HNC) patients undergoing chemoradiotherapy (CRT) who are ineligible for cisplatin have…”
Get full text

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer by Swiecicki, Paul L, Yilmaz, Emrullah, Rosenberg, Ari Joseph, Fujisawa, Takao, Bruce, Justine Yang, Meng, Changting, Wozniak, Michele, Zhao, Yongyun, Mihm, Michael, Kaplan, Jason, Gorla, Seema, Geiger, Jessica L

“…Despite advances in immunotherapy, unresectable recurrent/metastatic head and neck cancer (HNC) carries a poor prognosis, and effective treatments are needed…”
Get full text

Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial by Honma, Yoshitaka, Swiecicki, Paul L., Rosenberg, Ari Joseph, Hanna, Glenn J., Yang Bruce, Justine, Fujisawa, Takao, Muro, Kei, Kaplan, Jason B., Gorla, Seema Rao, Liu, Shubin, Meng, Changting, Geiger, Jessica Lyn

“…TPS148 Background: Novel treatment strategies are needed to treat recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) given the poor…”
Get full text

Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100 by Shen, Colette, Frakes, Jessica M., Hackman, Trevor G, Niu, Jiaxin, Weiss, Jared, Caudell, Jimmy J., Yang, George Q, Seiwert, Tanguy Y., Murgu, Septimiu, Kirtane, Kedar, Rolando, David, Tyan, Pavel, Vivar, Omar I, Gooi, Zhen, Juloori, Aditya, Rosenberg, Ari Joseph

“…6035 Background: Overcoming resistance to immune checkpoint inhibitors (ICIs) is a major clinical challenge. NBTXR3, a novel radioenhancer composed of…”
Get full text

Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follow‐Up by Rosenberg, Ari Joseph, Rademaker, Alfred, Hochster, Howard S., Ryan, Theresa, Hensing, Thomas, Shankaran, Veena, Baddi, Lisa, Mahalingam, Devalingam, Mulcahy, Mary F., Benson, Al B.

“…Lessons Learned Adding docetaxel to the modified FOLFOX7 backbone (DOF) is a feasible three‐drug combination therapy for advanced gastric cancer with high…”
Get full text